Peregrine to Present at Stifel Nicolaus Healthcare Conference September 5, 2012 at 2:40 PM EDT
(firmenpresse) - TUSTIN, CA -- (Marketwire) -- 08/29/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the 2012 Stifel Nicolaus Healthcare Conference at The Four Seasons Hotel in Boston, Massachusetts on Wednesday, September 5, 2012 at 2:40 PM Eastern Daylight Time.
Peregrine's presentation will be webcast live and available for replay until September 19, 2012 at:
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at .
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.08.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 1146584
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TUSTIN, CA
Phone:
Kategorie:
Trials
Anmerkungen:
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peregrine to Present at Stifel Nicolaus Healthcare Conference September 5, 2012 at 2:40 PM EDT
"
steht unter der journalistisch-redaktionellen Verantwortung von
Peregrine Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
